Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
作者： Susumu Kobayashi , Hannah M. Canepa , Alexandra S. Bailey , Sohei Nakayama , Norihiro Yamaguchi
DOI: 10.1097/JTO.0B013E3182781E35
关键词:
摘要: … We analyzed the EGFR mutation pattern of 79 cases of NSCLC harboring EGFR mutations and … data for patients with NSCLCs with compound EGFR mutations treated with EGFR TKIs. …
jto.org
sci-hub.se 参考文章(19)
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238
YR Chen, YN Fu, CH Lin, ST Yang, SF Hu, YT Chen, SF Tsai, SF Huang, None, Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants Oncogene. ,vol. 25, pp. 1205- 1215 ,(2006) , 10.1038/SJ.ONC.1209159
Wee-Lee Yeo, Gregory J. Riely, Beow Y. Yeap, Michelle W. Lau, Jeremy L. Warner, Kelly Bodio, Mark S. Huberman, Mark G. Kris, Daniel G. Tenen, William Pao, Susumu Kobayashi, Daniel B. Costa, Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. Journal of Thoracic Oncology. ,vol. 5, pp. 1048- 1053 ,(2010) , 10.1097/JTO.0B013E3181DD1386
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Jenn-Yu Wu, Shang-Gin Wu, Chih-Hsin Yang, Chien-Hung Gow, Yih-Leong Chang, Chong-Jen Yu, Jin-Yuan Shih, Pan-Chyr Yang, Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clinical Cancer Research. ,vol. 14, pp. 4877- 4882 ,(2008) , 10.1158/1078-0432.CCR-07-5123
Yasushi Yatabe, William Pao, James R. Jett, Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. Journal of Thoracic Oncology. ,vol. 7, pp. 775- 776 ,(2012) , 10.1097/JTO.0B013E318251980B
Issan Yee-San Tam, Elaine Lai-Han Leung, Vicky Pui-Chi Tin, Daniel Tsin-Tien Chua, Alan Dart-Loon Sihoe, Lik-Cheung Cheng, Lap-Ping Chung, Maria Pik Wong, Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations Molecular Cancer Therapeutics. ,vol. 8, pp. 2142- 2151 ,(2009) , 10.1158/1535-7163.MCT-08-1219
Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Romel Somwar, Allan R. Li, Maureen F. Zakowski, Anne Chiang, Guangli Yang, Ouathek Ouerfelli, Mark G. Kris, Marc Ladanyi, Vincent A. Miller, William Pao, Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors Clinical Cancer Research. ,vol. 12, pp. 6494- 6501 ,(2006) , 10.1158/1078-0432.CCR-06-1570
Daniel B Costa, Balázs Halmos, Amit Kumar, Susan T Schumer, Mark S Huberman, Titus J Boggon, Daniel G Tenen, Susumu Kobayashi, BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations PLOS Medicine. ,vol. 4, pp. 1669- 1680 ,(2007) , 10.1371/JOURNAL.PMED.0040315
Lecia V. Sequist, Benjamin Besse, Thomas J. Lynch, Vincent A. Miller, Kwok K. Wong, Barbara Gitlitz, Keith Eaton, Charles Zacharchuk, Amy Freyman, Christine Powell, Revathi Ananthakrishnan, Susan Quinn, Jean-Charles Soria, Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor:Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 28, pp. 3076- 3083 ,(2010) , 10.1200/JCO.2009.27.9414